Post-VX exposure treatment of rats with engineered phosphotriesterases
Post-VX exposure treatment of rats with engineered phosphotriesterases
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
The biologically stable and highly toxic organophosphorus nerve agent (OP) VX poses a major health threat. Standard medical therapy, consisting of reactivators and competitive muscarinic receptor antagonists, is insufficient. Recently, two engineered mutants of the
Brevundimonas diminuta
phosphotriesterase (PTE) with enhanced catalytic effici...
Alternative Titles
Full title
Post-VX exposure treatment of rats with engineered phosphotriesterases
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837561
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837561
Other Identifiers
ISSN
0340-5761
E-ISSN
1432-0738
DOI
10.1007/s00204-021-03199-6
